With fewer exacerbations, there's something NUCALA (mepolizumab) about him

NUCALA is indicated for the add-on maintenance treatment of adult patients with inadequately controlled chronic obstructive pulmonary disease (COPD) and an eosinophilic phenotype. NUCALA is not indicated for the relief of acute bronchospasm.

NUCALA HELPED:

PREVENT
EXACERBATIONS

Significant reductions in overall moderate or severe exacerbations* per year with NUCALA + SOC† vs placebo + SOC,† primary endpoints1,2:

MATINEE: 21% reduction at Weeks 52-104: NUCALA, 0.80 (n=403) vs placebo, 1.01 (n=401). (RR: 0.79; P=0.01).‡

METREX: 18% reduction at Week 52: NUCALA, 1.40 (n=233) vs placebo, 1.71 (n=229). (RR: 0.82; P=0.04).‡

EXACERBATION DATA

REDUCE
HOSPITAL VISITS§ DUE TO EXACERBATIONS1

The only biologic studied for 2 years to help reduce hospital visits§ due to exacerbations1

35% reduction in exacerbations requiring hospitalization and/or ED visit per year vs placebo. NUCALA, 0.13 vs placebo, 0.20 at Weeks 52-104; RR: 0.65 (95% CI: 0.43, 0.96).

NUCALA + SOC,† 0.13/year (n=403) vs placebo + SOC,† 0.20/year (n=401) at Weeks 52-104; RR: 0.65 (95% CI: 0.43, 0.96).

MATINEE secondary endpoint; not statistically significant due to failure earlier in the testing hierarchy.

§Hospitalizations/ED visits of any length.

SEE THE DATA

IMPLEMENT
A SIMPLE, ONCE-MONTHLY||
COPD BIOLOGIC DOSING SCHEDULE

See the options for at-home or in-office administration. Watch “how-to” videos and download the full Instructions for Use.

||Every 4 weeks.

DOSING DETAILS

*Moderate exacerbations (worsening of COPD symptoms) requiring treatment with systemic corticosteroids and/or antibiotics. Severe exacerbations defined as those requiring hospitalization (≥24 hours) or resulting in death.3

†SOC=ICS + LABA + LAMA.

‡Mean rate of exacerbations in previous year: MATINEE 2.3; METREX 2.5.1,2

MATINEE/METREX study designs

Learn more about the established safety profile of NUCALA in COPD.

COPD patient Nicholas throwing a Frisbee in an outdoor pool

PATIENT TYPES WHO MAY BENEFIT FROM NUCALA 

In your practice, you may know these types of patients with COPD.

SEE NUCALA PATIENT PROFILES

COPD patient Nicholas throwing a Frisbee in an outdoor pool

PATIENT TYPES WHO MAY BENEFIT FROM NUCALA 

In your practice, you may know these types of patients with COPD.

SEE NUCALA PATIENT PROFILES

COPD patient Anna holding stuffed animals with her granddaughter

GETTING PATIENTS STARTED ON NUCALA

Help patients start and stay on NUCALA with resources for enrollment and access to treatment. Are you a biologic coordinator? These resources are for you.

VISIT NUCALA SUPPORT & ACCESS

COPD patient Anna holding stuffed animals with her granddaughter

GETTING PATIENTS STARTED ON NUCALA

Help patients start and stay on NUCALA with resources for enrollment and access to treatment. Are you a biologic coordinator? These resources are for you.

VISIT NUCALA SUPPORT & ACCESS

BEC=blood eosinophil count; CI=confidence interval; ED=emergency department; ICS=inhaled corticosteroid; LABA=long-acting beta2-agonist; LAMA=long-acting muscarinic antagonist; RR=rate ratio; SOC=standard of care.

Make NUCALA your first-choice biologic to treat 5 chronic inflammatory diseases

NUCALA is for SEA, CRSwNP, COPD, EGPA, or HES.

EXPLORE INDICATIONS